CYTORI THERAPEUTICS, INC. (NASDAQ:CYTX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On July 11, 2019, at the 2019 Annual Meeting of Stockholders (the “Annual Meeting”) of Cytori Therapeutics, Inc. (the “Company”), the Company’s stockholders approved the amendment and restatement of the Company\’s 2014 Equity Incentive Plan (the “Restated Plan”). The Restated Plan provided for an increase in the number of shares of common stock reserved for issuance to awards thereunder from 1,040,013 shares to 5,040,013 shares, the limit on the number of shares that may be issued to incentive stock options under the Restated Plan was increased from 1,040,013 shares to 5,040,013 shares, and the term of the Restated Plan was extended through April 2029. The information regarding the Restated Plan set forth under, or incorporated by reference into, Item 5.07 below, is incorporated into this Item 5.02 by reference.
The terms and conditions of the Restated Plan are described in the section entitled “Proposal #3—Approval of Amendment and Restatement of the Cytori Therapeutics, Inc. 2014 Equity Incentive Plan” in the Company’s definitive proxy statement filed with the Securities and Exchange Commission (the “SEC”) on April 19, 2019. The Company’s directors and officers are eligible to participate in the Restated Plan. The foregoing description of the Restated Plan does not purport to be complete and is qualified in its entirety by reference to the complete text of the Restated Plan, which is filed herewith as Exhibit 10.1 and incorporated herein by reference.
Item 5.07Submission of Matters to a Vote of Security Holders
Broker Non-Votes: 10,552,511
Broker Non-Votes: 10,552,511
Broker Non-Votes: 10,552,511
Item 9.01 Financial Statements and Exhibits.
The following exhibits are furnished as part of this Current Report on Form 8-K:
(d) Exhibits.
About CYTORI THERAPEUTICS, INC. (NASDAQ:CYTX)
Cytori Therapeutics, Inc. (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products. It is focused on developing primary product, Cytori Cell Therapy, for patients with scleroderma hand dysfunction, orthopedic disorders, cardiovascular disease, urinary incontinence and thermal burns, including those complicated by radiation. Its cellular therapeutics are collectively known by the name, Cytori Cell Therapy, which consists of a heterogeneous population of specialized cells, including stem cells that are involved in response to injury, repair and healing. These cells are extracted from an adult patient’s own adipose tissue using its automated, enzymatic, sterile Celution System devices and consumable sets at the place where the patient is receiving their care.